Investigation of a potential protein biomarker signature that may predict clinical benefit of NT-I7 and pembrolizumab in patients with cold gastrointestinal tumors.

Wednesday, June 19, 2024

Dr. Minal Barve

Read the Story Here

View the abstract via the above link.

ASCO Poster for Trial 20-13

ASCO 2024 Poster for Trial 20-13

Click here to view the ASCO 2024 Poster for Trial 20-13 in Full-Size.

Related Posts

Discover more posts like this.

Preliminary Clinical Activity of RMC-6236, a First-in-Class, RAS-Selective, Tri-Complex RASMULTI(ON) Inhibitor in Patients with KRAS-Mutant Pancreatic Ductal Adenocarcinoma (PDAC) and Non-Small Cell Lung Cancer (NSCLC)

Aug 23, 2024

Dr. Minal Barve

STX-478, a mutant-selective PI3Kαinhibitor clinical candidate with a best-in-class profile: Pharmacology and therapeutic activity as monotherapy and in combination in breast cancer xenograft models

Aug 21, 2024

Dr. Douglas Orr

BT8009-100 Phase I/II Study of Novel Bicyclic Peptide and MMAE Conjugate BT8009 in Patients with Advanced Malignancies Associated with Nectin-4 Expression

Aug 21, 2024

Dr. Minal Barve
See All Posts